304 related articles for article (PubMed ID: 31174485)
1. Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases.
Bustamante Eduardo M; Popovici V; Imboden S; Aebi S; Ballabio N; Altermatt HJ; Günthert A; Jaggi R
BMC Cancer; 2019 Jun; 19(1):549. PubMed ID: 31174485
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
3. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.
Wallden B; Storhoff J; Nielsen T; Dowidar N; Schaper C; Ferree S; Liu S; Leung S; Geiss G; Snider J; Vickery T; Davies SR; Mardis ER; Gnant M; Sestak I; Ellis MJ; Perou CM; Bernard PS; Parker JS
BMC Med Genomics; 2015 Aug; 8():54. PubMed ID: 26297356
[TBL] [Abstract][Full Text] [Related]
4. Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes.
Caan BJ; Sweeney C; Habel LA; Kwan ML; Kroenke CH; Weltzien EK; Quesenberry CP; Castillo A; Factor RE; Kushi LH; Bernard PS
Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):725-34. PubMed ID: 24521998
[TBL] [Abstract][Full Text] [Related]
5. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.
Filipits M; Nielsen TO; Rudas M; Greil R; Stöger H; Jakesz R; Bago-Horvath Z; Dietze O; Regitnig P; Gruber-Rossipal C; Müller-Holzner E; Singer CF; Mlineritsch B; Dubsky P; Bauernhofer T; Hubalek M; Knauer M; Trapl H; Fesl C; Schaper C; Ferree S; Liu S; Cowens JW; Gnant M;
Clin Cancer Res; 2014 Mar; 20(5):1298-305. PubMed ID: 24520097
[TBL] [Abstract][Full Text] [Related]
6. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
Martin M; Brase JC; Ruiz A; Prat A; Kronenwett R; Calvo L; Petry C; Bernard PS; Ruiz-Borrego M; Weber KE; Rodriguez CA; Alvarez IM; Segui MA; Perou CM; Casas M; Carrasco E; Caballero R; Rodriguez-Lescure A
Breast Cancer Res Treat; 2016 Feb; 156(1):81-9. PubMed ID: 26909792
[TBL] [Abstract][Full Text] [Related]
7. Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion.
Lluch A; González-Angulo AM; Casadevall D; Eterovic AK; Martínez de Dueñas E; Zheng X; Guerrero-Zotano Á; Liu S; Pérez R; Chen K; Chacón JI; Mills GB; Antolín S; Blancas I; López-Serra P; Carrasco E; Caballero R; Prat A; Rojo F; Gonzalez-Perez A; Meric-Bernstam F; Albanell J
Eur J Cancer; 2019 Oct; 120():54-64. PubMed ID: 31491604
[TBL] [Abstract][Full Text] [Related]
8. Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes.
Kumar N; Zhao D; Bhaumik D; Sethi A; Gann PH
BMC Cancer; 2019 Mar; 19(1):215. PubMed ID: 30849944
[TBL] [Abstract][Full Text] [Related]
9. The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.
Jensen MB; Lænkholm AV; Nielsen TO; Eriksen JO; Wehn P; Hood T; Ram N; Buckingham W; Ferree S; Ejlertsen B
Breast Cancer Res; 2018 Jul; 20(1):79. PubMed ID: 30053900
[TBL] [Abstract][Full Text] [Related]
10. Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer.
Varga Z; Sinn P; Fritzsche F; von Hochstetter A; Noske A; Schraml P; Tausch C; Trojan A; Moch H
PLoS One; 2013; 8(3):e58483. PubMed ID: 23505515
[TBL] [Abstract][Full Text] [Related]
11. Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse.
Falato C; Tobin NP; Lorent J; Lindström LS; Bergh J; Foukakis T
Mol Oncol; 2016 Apr; 10(4):517-25. PubMed ID: 26651914
[TBL] [Abstract][Full Text] [Related]
12. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.
Cejalvo JM; Martínez de Dueñas E; Galván P; García-Recio S; Burgués Gasión O; Paré L; Antolín S; Martinello R; Blancas I; Adamo B; Guerrero-Zotano Á; Muñoz M; Nucíforo P; Vidal M; Pérez RM; Chacón López-Muniz JI; Caballero R; Peg V; Carrasco E; Rojo F; Perou CM; Cortés J; Adamo V; Albanell J; Gomis RR; Lluch A; Prat A
Cancer Res; 2017 May; 77(9):2213-2221. PubMed ID: 28249905
[TBL] [Abstract][Full Text] [Related]
13. Molecular Drivers of Onco
Buus R; Sestak I; Kronenwett R; Ferree S; Schnabel CA; Baehner FL; Mallon EA; Cuzick J; Dowsett M
J Clin Oncol; 2021 Jan; 39(2):126-135. PubMed ID: 33108242
[TBL] [Abstract][Full Text] [Related]
14. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Dowsett M; Sestak I; Lopez-Knowles E; Sidhu K; Dunbier AK; Cowens JW; Ferree S; Storhoff J; Schaper C; Cuzick J
J Clin Oncol; 2013 Aug; 31(22):2783-90. PubMed ID: 23816962
[TBL] [Abstract][Full Text] [Related]
15. Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens.
Nielsen T; Wallden B; Schaper C; Ferree S; Liu S; Gao D; Barry G; Dowidar N; Maysuria M; Storhoff J
BMC Cancer; 2014 Mar; 14():177. PubMed ID: 24625003
[TBL] [Abstract][Full Text] [Related]
16. The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptor-positive postmenopausal women with special histological subtypes.
Laenkholm AV; Jensen MB; Eriksen JO; Buckingham W; Ferree S; Nielsen TO; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):44-50. PubMed ID: 29202609
[TBL] [Abstract][Full Text] [Related]
17. Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients.
Laurberg T; Alsner J; Tramm T; Jensen V; Lyngholm CD; Christiansen PM; Overgaard J
Acta Oncol; 2017 Jan; 56(1):59-67. PubMed ID: 27846764
[TBL] [Abstract][Full Text] [Related]
18. Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.
Fernandez-Martinez A; Pascual T; Perrone G; Morales S; de la Haba J; González-Rivera M; Galván P; Zalfa F; Amato M; Gonzalez L; Prats M; Rojo F; Manso L; Paré L; Alonso I; Albanell J; Vivancos A; González A; Matito J; González S; Fernandez P; Adamo B; Muñoz M; Viladot M; Font C; Aya F; Vidal M; Caballero R; Carrasco E; Altomare V; Tonini G; Prat A; Martin M
Oncotarget; 2017 Mar; 8(13):21930-21937. PubMed ID: 28423537
[TBL] [Abstract][Full Text] [Related]
19. RNA-Seq of Circulating Tumor Cells in Stage II-III Breast Cancer.
Lang JE; Ring A; Porras T; Kaur P; Forte VA; Mineyev N; Tripathy D; Press MF; Campo D
Ann Surg Oncol; 2018 Aug; 25(8):2261-2270. PubMed ID: 29868978
[TBL] [Abstract][Full Text] [Related]
20. Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer.
Haynes BP; Schuster G; Buus R; Alataki A; Ginsburg O; Quang LH; Han PT; Khoa PH; Van Dinh N; Van To T; Clemons M; Holcombe C; Osborne C; Evans A; Skene A; Sibbering M; Rogers C; Laws S; Noor L; Cheang MCU; Cleator SJ; Smith IE; Dowsett M
Breast Cancer Res Treat; 2021 Nov; 190(2):295-305. PubMed ID: 34524591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
